Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Daniel R Van Langenberg"'
Autor:
Anuj Bohra, Declan J Connoley, Danny Con, Jonathan P Segal, Olga Niewiadomski, Abhinav Vasudevan, Daniel R Van Langenberg, Numan Kutaiba
Publikováno v:
Intestinal Research, Vol 22, Iss 2, Pp 152-161 (2024)
Background/Aims Assessment of quality of magnetic resonance enterography (MRE) in small bowel Crohn’s disease (CD) activity evaluation has received little attention. We assessed the impact of bowel distention and motion artifact on MRE activity ind
Externí odkaz:
https://doaj.org/article/7c8aa4d5179045f69c8138f3e4c072f0
Autor:
Anuj Bohra, Diana Lewis, Jonathan P Segal, Abhinav Vasudevan, Daniel R Van Langenberg, Olga Niewiadomski
Publikováno v:
JGH Open, Vol 7, Iss 12, Pp 966-973 (2023)
Abstract Background and Aim Capsule endoscopy allows the direct visualization of the small bowel. We examined the diagnostic utility of a new modality, namely panenteric Crohn's capsule endoscopy (CE), in detecting active small‐bowel Crohn's diseas
Externí odkaz:
https://doaj.org/article/07cbc023739f428ca89a7c8686765274
Publikováno v:
Intestinal Research, Vol 20, Iss 1, Pp 101-113 (2022)
Background/Aims The residual risk of colectomy after infliximab salvage in steroid-refractory acute severe ulcerative colitis (ASUC) is required to inform the need for subsequent maintenance biologic therapy. The aim of this study was to determine th
Externí odkaz:
https://doaj.org/article/57c982e79a02456dbd0ebd612ca61013
Autor:
Timothy P. Hanrahan, Robbie Chan, Daniel Tassone, Nik S. Ding, Chamara Basnayake, Julien Schulberg, Abhinav Vasudevan, Michael Kamm, Michael De Gregorio, Daniel R. van Langenberg, Ola Niewiadomski
Publikováno v:
Future Pharmacology, Vol 2, Iss 4, Pp 669-680 (2022)
Background: Despite proven efficacy of biologics in inflammatory bowel disease (IBD), many exhibit primary non-response or secondary loss of response and switch to subsequent biologic(s). Here, we identified early predictors of second- and/or third-l
Externí odkaz:
https://doaj.org/article/5a298431f5a84a679f3e58eebe975873
Publikováno v:
Gastrointestinal Disorders, Vol 4, Iss 4, Pp 249-262 (2022)
Crohn’s disease is a chronic inflammatory disease affecting the gastrointestinal tract. Expert guidelines now recommend regular objective assessments as part of a treat-to-target approach. Intestinal ultrasound provides a noninvasive, patient-frien
Externí odkaz:
https://doaj.org/article/2296311c7a1e4064882da0b03386b142
Autor:
Anuj Bohra, Ghada Mohamed, Abhinav Vasudevan, Diana Lewis, Daniel R. Van Langenberg, Jonathan P. Segal
Publikováno v:
Biomedicines, Vol 11, Iss 5, p 1408 (2023)
Introduction: Currently, faecal calprotectin (FC) is the predominate faecal biomarker utilised in clinical practice to monitor Crohn’s disease (CD) activity. However, there are several potential faecal biomarkers described in the literature. We per
Externí odkaz:
https://doaj.org/article/ca858f0b7227472ba6bb5df59c651b1a
Publikováno v:
Diagnostics, Vol 12, Iss 10, p 2533 (2022)
Magnetic resonance enterography (MRE) is one of the most highly utilised tools in the assessment of patients with small bowel Crohn’s disease (CD). As a non-invasive modality, it has both patient and procedure-related advantages over ileocolonoscop
Externí odkaz:
https://doaj.org/article/baf7d4da9af34af7836f2a521162e40d
Publikováno v:
Journal of Gastroenterology and Hepatology. 38:724-732
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cd1b80d67292324fabb226bcdee83c6
https://doi.org/10.1111/jgh.16133
https://doi.org/10.1111/jgh.16133
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 10 (2019)
Background: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared. Methods: This single-center retrospective cohort study of i
Externí odkaz:
https://doaj.org/article/b132196cde284fdcbd453cb75e2f0d0b
Publikováno v:
Intestinal Research, Vol 20, Iss 1, Pp 101-113 (2022)
Background/Aims: The residual risk of colectomy after infliximab salvage in steroid-refractory acute severe ulcerative colitis (ASUC) is required to inform the need for subsequent maintenance biologic therapy. The aim of this study was to determine t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ece56737235de6d1dc3a44892fdb32cd
https://doi.org/10.5217/ir.2020.00146
https://doi.org/10.5217/ir.2020.00146